Ready to start planning your care? Call us at $\frac{800-525-2225}{100}$ to make an appointment.




Memorial Sloan Kettering Cancer Center

Make an Appointment

MEMORIAL HOSPITAL RESEARCH LABORATORIES

Refer a Patient Treatment The Nai-Kong Cheung Lab


ABOUT US Our mission, vision & core values Leadership History Equality, diversity & inclusion Annual report Give to MSK



Nai-Kong V. Cheung, MD, PhD Enid A. Haupt Chair in Pediatric Oncology, Pediatrics

My lab focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

View Lab Overview



Featured News



At Work: Physician-Scientist Nai-Kong Cheung

Meet pediatric oncologist Nai-Kong Cheung, whose research into solid tumors is creating new hope for children with cancer.

Publications Highlights

Yankelevich M, Thakur A, Modak S, Chu R, Taub J, Martin A, Schalk DL, Schienshang A, Whitaker S, Rea K, Lee DW, Liu Q, Shields A, Cheung NK, Lum LG. <u>Targeting refractory/recurrent neuroblastoma and osteosarcoma with anti-</u> <u>CD3×anti-GD2 bispecific antibody armed T cells.</u> J Immunother Cancer. 2024 Mar 21;12(3):e008744. doi: 10.1136/jitc-2023-008744 Kramer K, Pandit-Taskar N, Kushner BH, Zanzonico P, Humm JL, Tomlinson U, Donzelli M, Wolden SL, Haque S, Dunkel I, Souweidane MM, Greenfield JP, Tickoo S, Lewis JS, Lyashchenko SK, Carrasquillo JA, Chu B, Horan C, Larson SM, Cheung NV, Modak S. <u>Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS</u> <u>malignancies</u>. J Hematol Oncol. 2022 Nov 12;15(1):165. doi: 10.1186/s13045-022-01383-4.

Park JA and Cheung NK. <u>Overcoming tumor heterogeneity by ex vivo arming of T cells using multiple bispecific</u> <u>antibodies</u>. J Immunother Cancer. 2022 Jan;10(1):e003771. doi: 10.1136/jitc-2021-003771.

Hoseini SS, Vadlamudi M, Espinosa-Cotton M, Tran H, Feng Y, Guo HF, Xu H, Cheung I, Cheung NK. <u>T cell engaging</u> <u>bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia</u>. J Immunother Cancer. 2021, May;9(5):e002509. doi: 10.1136/jitc-2021-002509.

Xu H, Buhtoiarov IN, Guo HF, Cheung NK. <u>A novel multimeric IL15/IL15Rα-Fc complex to enhance cancer</u> <u>immunotherapy</u>. Oncoimmunology. 2021 Mar; 10(1):1893500. <u>doi: 10.1080/2162402X.2021.1893500</u>.

View All Publications

People

Nai-Kong V. Cheung, MD, PhD

inid A. Haupt Chair in Pediatric Oncology, Pediatrics

Physician-scientist Nai-Kong Cheung focuses on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

MD, PhD (Immunology), Harvard Medical School

☐ <u>cheungn@mskcc.org</u>

Email Address


<u>646-888-2313</u>

Office Phone

View physician profile

Physician profile

Members



Collon Research Fellow

reng Senior Research Assistant

Guo

Research Assistant/Specialist









Alan Long Research Scholar


Aiza Malik Research Technician


Jeong A Park Research Fellow

Yiwei Liu

Senior Research Scientist

Mauricio Rendon-Bernot Clinical Fellow





Hoa Tran Senior Research Assistant

Xu Senior Research Scientist

Hong

Lab Alumni +

Lab Affiliations

+

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Career Opportunities

Apply now

Get in Touch

- cheungn@mskcc.org
 Lab Head Email
- 646-888-2313 Office Phone
- 646-888-2320 Lab Phone

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report ("disclose") the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Nai-Kong V. Cheung discloses the following relationships and financial interests:

Abpro Inc Equity; Intellectual Property Rights Biotec Pharmacon Intellectual Property Rights

Eureka Therapeutics Inc Equity Y-mAbs Therapeutics, Inc. Equity; Intellectual Property Rights

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK's COI policies <u>here</u>. For questions regarding MSK's COI-related policies and procedures, email MSK's Compliance Office at <u>ecoi@mskcc.org</u>.

View all disclosures



About MSK

About us

Careers

<u>Giving</u>

Cancer Care

Adult cancer types

Child & teen cancer types

Integrative medicine

Nutrition & cancer

Find a doctor

Research & Education

Sloan Kettering Institute

Gerstner Sloan Kettering Graduate School

Graduate medical education

MSK Library

Communication preferences Cookie preferences Legal disclaimer Accessibility statement Privacy policy Price transparency Public notices © 2024 Memorial Sloan Kettering Cancer Center